Evaristo Maiello
Overview
Explore the profile of Evaristo Maiello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
3011
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pinto C, Lonardi S, Maiello E, Martinelli E, Prisciandaro M, Salvatore L, et al.
Front Oncol
. 2025 Feb;
14:1502185.
PMID: 39911824
The prolongation of survival along with the preservation of quality of life, possibly avoiding harmful cumulative toxicities, is the primary therapeutic aim for patients with metastatic colorectal cancer (mCRC) in...
2.
Parrella P, Barbano R, Jonas K, Fontana A, Barile S, Rendina M, et al.
Biomedicines
. 2024 Nov;
12(11).
PMID: 39595190
MicroRNAs are well established as master regulators of carcinogenesis and potential biomarkers in breast cancer (BC). In a preliminary effort, we found miR-27a-5p to be significantly downregulated in experimentally derived...
3.
Ascierto P, Mandala M, Ferrucci P, Guidoboni M, Rutkowski P, Ferraresi V, et al.
NEJM Evid
. 2024 Sep;
3(10):EVIDoa2400087.
PMID: 39315864
Background: The impact of the order of treatment with checkpoint inhibitors or BRAF/MEK inhibitors on the development of brain metastases in patients with metastatic unresectable V600-mutant melanoma is unknown. The...
4.
Villani A, Fontana A, Panebianco C, Ferro C, Copetti M, Pavlovic R, et al.
Gut Microbes
. 2024 Jul;
16(1):2375483.
PMID: 38972056
Pancreatic cancer has a dismal prognosis, as it is often diagnosed at stage IV of the disease and is characterized by metastatic spread. Gut microbiota and its metabolites have been...
5.
Martinelli E, Ciardiello D, Martini G, Napolitano S, Del Tufo S, DAmbrosio L, et al.
Clin Drug Investig
. 2024 Jun;
44(7):541-548.
PMID: 38886336
Background: CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic colorectal cancer (mCRC). Objective:...
6.
Maiorano B, Schinzari G, Carbone C, Piro G, Rossi E, Di Maio M, et al.
Front Immunol
. 2024 May;
15:1401214.
PMID: 38799450
Background: Avelumab maintenance after first-line platinum-based chemotherapy represents a cornerstone for the treatment of metastatic urothelial carcinoma (mUC). However, identifying prognostic biomarkers is paramount for optimizing patients' benefits while minimizing...
7.
Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti M, et al.
Breast
. 2024 Apr;
75:103725.
PMID: 38615483
Background: Optimizing chemotherapy to achieve disease and symptoms control is a noteworthy purpose in advanced breast cancer (ABC). We reported the activity and quality of life of a phase II...
8.
Giaccherini M, Giaccherini M, Rende M, Gentiluomo M, Gentiluomo M, Corradi C, et al.
Mutagenesis
. 2024 Apr;
PMID: 38606763
Pleiotropic variants (i.e., genetic polymorphisms influencing more than one phenotype) are often associated with cancer risk. A scan of pleiotropic variants was successfully conducted ten years ago in relation to...
9.
Maiorano B, Di Maio M, Cerbone L, Maiello E, Procopio G, Roviello G
JAMA Netw Open
. 2024 Mar;
7(3):e241215.
PMID: 38446479
Importance: Immune checkpoint inhibitors (ICIs) have broadened the metastatic urothelial carcinoma (mUC) therapeutic scenario. The association of programmed death ligand 1 (PD-L1) with response and survival in patients treated with...
10.
Unal P, Lu Y, Bueno-de-Mesquita B, van Eijck C, Talar-Wojnarowska R, Szentesi A, et al.
Hum Genomics
. 2024 Feb;
18(1):12.
PMID: 38308339
Genome-wide association studies (GWAS) are a powerful tool for detecting variants associated with complex traits and can help risk stratification and prevention strategies against pancreatic ductal adenocarcinoma (PDAC). However, the...